No Data
Key Deals This Week: Google, Nvidia, EsoBiotec SA, Coinbase Global and More
Shenzhen Kangtai Biological Products (300601.SZ): Signed the "Economic Development Cooperation Agreement" and the "List of Terms".
On March 21, Glonghui reported that Shenzhen Kangtai Biological Products (300601.SZ) announced that it would convene the third meeting of the eighth Board of Directors on March 21, 2025, to review and approve the proposal on signing and establishing a joint venture through external investment. After careful discussion, the company plans to establish a deep strategic partnership with AstraZeneca Investment (China) Co., Ltd. (hereinafter referred to as "AstraZeneca") focusing on vaccines, and to set up a joint venture in the Peking Economic and Technological Development Zone (hereinafter referred to as "Development Zone"), serving as a platform for developing innovative vaccines in China, targeting the Chinese market and
AstraZeneca (AZN.US) "Acatinib capsules" have been approved for a new indication in the domestic market.
AstraZeneca (AZN.US) "Axitinib capsules" have been approved for a new indication in the domestic market.
AstraZeneca (AZN.US) is expanding its Business in China and plans to invest 2.5 billion USD to build a Global Strategy research and development center in Peking.
AstraZeneca (AZN.US) announced on Friday that it will invest $2.5 billion to establish its sixth Global Strategy R&D center in Peking, which will also be its second R&D center in China.
Express News | Syneron Bio Announces Strategic Collaboration With AstraZeneca
AstraZeneca Expands in China With a $2.5B Investment in Beijing
